IGC Pharma Inc

IGC Pharma Inc is a clinicalstage pharmaceutical company that is focused on Alzheimers disease developing innovative solutions to address this devastating illness It has two investigational drug assets targeting Alzheimers disease IGCAD1 which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimers and TGR63 that is in preclinical development In addition to its drug development pipeline IGC Pharma seeks to leverage artificial intelligence AI for Alzheimers research The company was founded by Ram Mukunda on April 29 2005 and is headquartered in Potomac MD